文献速递免疫规划妇幼与学校卫生卫生政策与健康促进

孕期接种 mRNA 疫苗比腺病毒载体疫苗诱导更强的免疫应答:对大流行准备的意义

Enhanced immune responses to mRNA compared with adenoviral vector COVID-19 vaccines during pregnancy: implications for pandemic preparedness.
PubMed 文献 · Vaccine · 2026-01-07

本研究为前瞻性队列研究,比较孕期接种腺病毒载体疫苗(ChadOx1-S,N=17)与 mRNA 疫苗(BNT162b2 N=42 或 mRNA-1273 N=5)后血液和母乳中的体液与细胞免疫应答。结果显示 mRNA 疫苗接种者抗 RBD IgG 滴度、亲和力、中和能力及 S1/S2 特异性 CD154 CD4+ T 细胞应答均显著更高,脐带血抗 RBD IgG 和 NAb 滴度也更高;产后 mRNA 加强后两组免疫应答相当。提示孕期紧急使用可能优先选择 mRNA 疫苗。

要点

  • 孕期接种 mRNA 疫苗比腺病毒载体疫苗产生更高滴度、更强亲和力和中和能力的抗 RBD IgG。
  • mRNA 疫苗组脐带血抗 RBD IgG 和中和抗体滴度显著高于腺病毒载体疫苗组。
  • 产后 mRNA 加强后两组免疫应答相当,提示 mRNA 疫苗可优先用于孕期应急接种。

核心结论

  • 孕期接种 mRNA COVID-19 疫苗比腺病毒载体疫苗诱导更快速、更强的免疫应答。
  • mRNA 疫苗可能更适合孕期紧急使用,并支持未来母体疫苗开发和大流行准备推荐。

研究设计与样本

  • 前瞻性队列研究,孕期受试者 85% 为 COVID-19 未感染,接种至少一剂腺病毒载体疫苗 ChadOx1-S(N=17)或 mRNA 疫苗 BNT162b2(N=42)或 mRNA-1273(N=5)。
  • 在每次疫苗剂量前后及分娩时采集血液样本,产后 12 周内采集母乳样本,随访至产后 mRNA 加强接种后 28-35 天(BNT162b2 N=23;mRNA-1273 N=25)。
  • 主要结局为腺病毒载体疫苗组与 mRNA 疫苗组免疫应答比较。

主要发现

  • mRNA 疫苗接种者第二剂后第 28 天抗 RBD IgG 滴度显著更高,亲和力和中和能力更强。
  • mRNA 疫苗接种者 S1 和 S2 特异性 CD154 CD4+ T 细胞应答更强。
  • mRNA 疫苗接种者分娩时脐带血抗 RBD IgG 和 NAb 滴度显著高于腺病毒载体疫苗接种者。
  • 产后 mRNA 加强接种后两组免疫应答相当。

临床怎么用

  • 孕期应急接种 COVID-19 疫苗时,可优先考虑 mRNA 疫苗以增强母体和新生儿免疫保护。
  • 未来母体疫苗开发和大流行准备推荐中可支持 mRNA 平台的使用。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

INTRODUCTION: Multiple SARS-CoV-2 vaccine types are available but the optimal platform for use in pregnancy remains unclear. This study compared humoral and cellular immune responses in blood and breastmilk following COVID-19 vaccination with different vaccine types during pregnancy. METHODS: In a prospective cohort study, pregnant individuals (85 % naïve for COVID-19) received at least one dose of either the adenoviral vector vaccine (AVV) ChadOx1-S (N = 17) or a messenger RNA vaccine (mRNAV) BNT162b2 (N = 42) or mRNA-1273 (N = 5) during pregnancy. Blood samples were taken at different timepoints before and after each vaccine dose, and at delivery. Breastmilk samples were collected up to 12 weeks postpartum. Follow-up continued until 28-35 days after postpartum mRNA booster vaccination (BNT162b2: N = 23; mRNA-1273: N = 25). The primary outcome was comparison of immune responses between the AVV and mRNAV group. RESULTS: mRNAV recipients showed significantly higher anti-RBD IgG titres, with greater avidity and neutralizing capacity, and stronger S1- and S2-specific CD154 CD4+ T-cell responses up to day 28 after the second vaccine dose. Cord blood from mRNAV recipients had significantly higher anti-RBD IgG and NAb titres at delivery compared to AV vaccinated individuals. After postpartum mRNA booster vaccination, immune responses were comparable between both groups. CONCLUSION: mRNA COVID-19 vaccination during pregnancy elicited more rapid and robust immune responses compared to AV vaccination. These findings suggest that mRNA vaccines may be preferable for emergency use during pregnancy and support their use in future maternal vaccine development and in pandemic preparedness recommendations. CLINICAL TRIAL REGISTRY: Clinicaltrials.govidentifier: NCT05618548.

来源:Vaccine,查看原文。版权归原作者所有。

引用

  1. De Brabandere L, Herzog SA, Desombere I, et al. Enhanced immune responses to mRNA compared with adenoviral vector COVID-19 vaccines during pregnancy: implications for pandemic preparedness. Vaccine. 2026. PMID: 41505852. doi:10.1016/j.vaccine.2025.128153

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。